spec sheet11 rows
VU0486846 is an experimental M1 muscarinic acetylcholine receptor positive allosteric modulator (an "M1 PAM"; it makes the M1 receptor respond more strongly to the brain's own acetylcholine rather than switching it on directly). It came out of the Vanderbilt neuroscience drug-discovery group and is prized as a "clean" research tool: it improves cognition in animal models without the agonist activity, seizures, and classic cholinergic side effects that plagued earlier M1 activators. It has been studied mostly in models of Alzheimer's disease, schizophrenia-related cognitive deficits, prion neurodegeneration, and Rett syndrome. It is a research compound with no human data.
- Boosts cognition without cholinergic side effects
- Pure PAM (no direct agonist activity), so no seizures in animal tests
- Reverses antipsychotic-induced cognitive deficits
- Disease-modifying signals in Alzheimer's models
- Improved memory in Alzheimer mouse models of both sexes
- Reduced microglial and astrocytic activation in the hippocampus of female Alzheimer mice
- Prolonged survival and maintained cognitive function in prion-infected mice
- Reversed the cognitive deficits induced by the atypical antipsychotic risperidone in rodents
- No cholinergic toxicity and no seizure liability in the species tested
Overview
The cleanest M1 tool compound in the literature and the one that made the case that cholinergic toxicity was never intrinsic to M1 itself. There is no human data at all, so every claim about it is a rodent claim.
- The compound that made the strongest case against ago-PAMs was never meant to become a drug; Vanderbilt built it explicitly as a rodent tool to prove that M1 potentiation and cholinergic toxicity are separable, and it has no human data at all.
- Its benefit in male and female APPswe/PSEN1 mice appears to run through different pathways; in females it reduced amyloid-beta oligomers and plaques, in males it improved cognition and lowered BACE1 while leaving plaque burden unchanged.
Mechanism
The M1 receptor is a major receptor in the and and is central to learning and memory; directly switching it on with an improves cognition but also triggers unwanted cholinergic effects and, with strong M1 "ago-PAMs", seizures. VU0486846 sidesteps this by acting as a pure positive modulator: it binds a site separate from where acetylcholine binds and amplifies the receptor's response to acetylcholine that is already present, rather than activating the receptor on its own [1][2]. In cells with high receptor reserve it shows only weak intrinsic activity, and in the prefrontal it produced no actions, no seizure liability at high brain exposures, and none of the classic cholinergic adverse events seen with ago-PAMs such as MK-7622 [2].
Despite that restraint it is procognitive: it improved performance in the novel object recognition memory test and, notably, reversed the cognitive deficits caused by the atypical antipsychotic risperidone, supporting M1 potentiation as a way to treat the cognitive symptoms of schizophrenia [2]. In Alzheimer's disease models (APPswe/PSEN1 mice), oral VU0486846 restored memory, eased anxiety-like behavior, and reduced amyloid-beta pathology, partly by shifting amyloid precursor protein processing away from the amyloid-forming route (lowering the enzyme BACE1 and raising the non-amyloidogenic enzyme ADAM10) and by damping the microglial and activation behind ; several of these effects were sex-specific [3][4][5]. Its M1 potentiation has also slowed molecular pathology and preserved cognition in a prion (misfolded-protein) neurodegeneration model [6], and improved auditory-processing neurophysiology in a Rett syndrome model, where the benefit followed an inverted-U dose pattern [7]. Chemically it is built on a benzomorpholine (benzoxazine) scaffold, and its development is a textbook case of the steep, unforgiving structure-activity relationships typical of -modulator programs [1][8].
receptor fingerprint
M1 receptorpositive allosteric modulator
APP processing (BACE1 / ADAM10)shifts to non-amyloidogenic
/ activationreduces
M1 (CHRM1)Positive allosteric modulator
Orthosteric site of M1No competition with orthosteric antagonist binding and no negative cooperativity with [3H]-NMS
Beta-arrestin associated M1 signallingEfficacy modulation comparable to the G protein pathway rather than arrestin-preferring
BACE1 and ADAM10 (amyloid precursor protein processing)Lowers BACE1 and raises ADAM10 in APPswe/PSEN1 hippocampus
Orthosteric siteno interaction (pure PAM)
Safetyrisks and cautions, not medical advice
There has been no human exposure, so nothing can be said about human safety; the compound was released as a laboratory tool and no clinical programme has been reported. In rodents and non-human primates it was reported free of the cholinergic adverse events that defined the class, and free of seizure liability at high brain exposures, which is the specific liability that stopped the ago-PAMs [2]. In Rett syndrome mice the dose response was an inverted U, with the auditory evoked potential benefit peaking at 3 mg/kg and lost at 10 and 30 mg/kg, so more is not better and the useful window is narrow [7]. The same study found no marked effect on basal electroencephalogram power or on epileptiform discharges in those mice, which is reassuring on the seizure question, but it was measured after acute dosing only and chronic electrophysiological safety has not been reported [7].
History
VU0486846 came out of the Warren Center for Neuroscience Drug Discovery at Vanderbilt, which scaffold-hopped from the quinolone core used by earlier M1 modulators to a benzomorpholine and published the optimisation campaign in 2018 [1]. It was released as a rodent tool compound rather than a clinical candidate, and its purpose was to test whether M1 potentiation could be separated from cholinergic toxicity at all; the answer, in the species tested, was yes [2]. Groups in Ottawa, Vancouver and Glasgow then used it as the probe: for amyloid pathology and cognition in APPswe/PSEN1 mice [5], for neuroinflammation in the same model, where it reduced Iba1-positive microglia and GFAP-positive astrocytes in the hippocampus of female mice [4], for prion-mediated neurodegeneration, where chronic treatment prolonged survival and maintained cognitive function [6], and for Rett syndrome [7].
Reputation
Highly regarded as a tool, not as a drug. Its citation trail runs through academic pharmacology rather than industry pipelines, and its main contribution is the control it provided: an M1 modulator without agonism, without seizures and without cholinergic adverse events, which reframed the class failures as a property of particular molecules rather than of the target. Anyone quoting it as evidence that M1 potentiation helps people is overreaching, because it has never been given to one.
Subjective profileweighing the evidence above
A well-designed research tool with no human data. Avoiding the seizures and cholinergic side effects that sank earlier M1 activators is a real achievement in animals, but clean in mice is not safe in people, and its human pharmacokinetics are unknown. Nothing anyone should be dosing.
Resources
This entry is here for reference.
Research
- 2018first citedThe discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine…
- 2026most recentLow Agonism and Balanced Pathway Modulation Distinguish an M1 Muscarinic Receptor Positive Allo…
- 1.The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core
- 2.A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity
- 3.Positive allosteric modulation of M1 mAChRs with VU0486846 reverses cognitive deficits in male APPswe/PSEN1ΔE9 Alzheimer's mice
- 4.A M1 muscarinic acetylcholine receptor-specific positive allosteric modulator VU0486846 reduces neurogliosis in female Alzheimer's mice
- 5.A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female APPswe/PSEN1ΔE9 mice
- 6.M1 muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative disease
- 7.Potentiation of the muscarinic acetylcholine receptor 1 modulates neurophysiological features in a mouse model of Rett syndrome
- 8.Enantioselective Desymmetrization of 3-Substituted Oxetanes: An Efficient Access to Chiral 3,4-Dihydro-2H-1,4-benzoxazines.
- 9.Low Agonism and Balanced Pathway Modulation Distinguish an M1 Muscarinic Receptor Positive Allosteric Modulator Lacking Cholinergic Adverse Effects
- 10.Membrane Proteome Remodeling in Female APP/PS1 Mice Following M1 Muscarinic Receptor Modulation Revealed by Peptidisc-Enabled DIA-MS
10 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What's an M1 PAM?
M1 is a muscarinic acetylcholine receptor that's big for memory. A positive allosteric modulator (PAM) doesn't switch it on itself; it binds a side pocket and makes the receptor respond more strongly to your own acetylcholine. That 'only when the signal is already there' behavior is why it avoids the side effects of drugs that force the receptor on.
Why does 'pure PAM' vs 'ago-PAM' matter?
Earlier M1 compounds had intrinsic agonist activity ('ago-PAMs') and over-activated M1, causing seizures and cholinergic side effects. VU0486846 was engineered to do almost nothing on its own, which in animals gave the cognitive benefit without those problems.
What has it actually been shown to do?
In rodents it improved object-recognition memory, reversed cognitive deficits from the antipsychotic risperidone, reduced amyloid and neuroinflammation in Alzheimer's models, slowed a prion neurodegeneration model, and improved brain-signal features in a Rett syndrome model. All preclinical.
Why do some studies mention sex differences?
In the Alzheimer's-model work several of its effects showed up differently in male versus female mice, a reminder that these findings are early and context-dependent, not settled.
Can I get it or take it?
It's a lab tool compound with zero human data, so no; it's used for research, not as a nootropic you'd dose.
Can I buy or take VU0486846?
No. It is a preclinical research tool with no human exposure and no clinical development programme. Suppliers sell it as a laboratory reagent for cell and animal work, which is not the same thing as something meant to be taken.
What is an ago-PAM, and why does it matter that VU0486846 is not one?
A positive allosteric modulator is supposed to do nothing on its own and only amplify the receptor's response to acetylcholine. An ago-PAM does both: it amplifies and it also activates the receptor directly. MK-7622, PF-06764427 and PF-06827443 were ago-PAMs, and the direct activation is what produced behavioural convulsions and disrupted cognition instead of improving it. VU0486846 was built to have as little of that direct activation as possible, and it was the compound that showed the two properties can be separated.
Does it lower amyloid?
In female APPswe/PSEN1 mice, yes; eight weeks of treatment reduced amyloid-beta oligomers and plaques and preserved hippocampal neurons, alongside lower BACE1 and higher ADAM10. In male mice of the same line it improved cognition and reduced BACE1 without changing oligomer or plaque burden. The honest reading is that the cognitive benefit and the amyloid effect can come apart, and that the pathway differs by sex.
How does it relate to TAK-071?
Same idea, reached by a different route. Both are M1 modulators that avoid cholinergic side effects by keeping their amplification of acetylcholine deliberately weak; Takeda tuned cooperativity down to an alpha value of 199, and a 2026 comparison of five M1 modulators found VU0486846 at the low end of both allosteric agonism and cooperativity. The difference is that TAK-071 went into humans and VU0486846 never left the laboratory.
If M1 is the right target, why did the older muscarinic drugs fail?
Because they hit the acetylcholine binding site itself. Milameline, sabcomeline and alvameline had to be pushed to a dose that activated M1, and at that dose they were also activating M2 in the heart and M3 in the gut and sweat glands. Every one of them ran into cholinergic adverse events before showing a convincing cognitive effect. Binding a separate site and amplifying the brain's own acetylcholine, weakly, is the design that came out of those failures.
Limitations of the evidence
- No human safety data
- Designed to avoid cholinergic toxicity/seizures, but unproven in people
- Pharmacokinetics and long-term effects unknown
Notes and cautions
- Research chemical, not a supplement